Asthika Goonewardene from Truist Financial set a price target of $38 for NASDAQ:EXEL, indicating a potential upside of 32.27%.
The Q3 2024 earnings call highlighted Exelixis’s financial results and strategic initiatives, with a focus on its flagship cancer treatment product, Cabometyx.
Exelixis’s stock price showed a slight increase, with a market capitalization of approximately $8.2 billion, reflecting its significant presence in the biotech sector.
Exelixis, Inc. (NASDAQ:EXEL) is a biotechnology company focused on developing and commercializing therapies for cancer treatment. The company is known for its flagship product, Cabometyx, which is used to treat various types of cancer. Exelixis operates in a competitive landscape with other biotech firms like Amgen and Gilead Sciences.
On October 30, 2024, Asthika Goonewardene from Truist Financial set a price target of $38 for EXEL. At the time, the stock was priced at $28.73, suggesting a potential upside of 32.27%. This optimistic outlook reflects confidence in Exelixis’s growth prospects and strategic direction, as discussed in their recent Q3 2024 earnings call.
The Q3 2024 earnings call, held on October 29, 2024, featured key executives like CEO Michael Morrissey and CFO Christopher Senner. The presence of analysts from major financial institutions such as Truist and Goldman Sachs underscores the investment community’s keen interest in Exelixis’s performance and future plans.
During the call, Exelixis shared insights into its financial results and strategic initiatives. The stock price, currently at $28.73, has shown a slight increase of 0.807% or $0.23. Throughout the trading day, EXEL fluctuated between $28.30 and $28.98, indicating market volatility and investor interest.
Exelixis’s market capitalization stands at approximately $8.2 billion, reflecting its significant presence in the biotech sector. With a 52-week high of $29.75 and a low of $19.20, the stock has experienced notable price movements. Today’s trading volume of 2,766,677 shares highlights active investor engagement.
